Arnica and the Management of Pain in Acute Musculoskeletal Extremity Injuries
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
In the Emergency Department, there is no standard of care for pain medication distribution
for children with an acute musculoskeletal injury when there is no fracture present.
Currently, ibuprofen is a favorable choice for the treatment, but studies have shown concern
for delayed healing activity associated with NSAIDs like Ibuprofen. Homeopathic Arnica
Montana is a well-established complimentary medicine and may provide a good alternative for
managing acute pain from musculoskeletal injuries, especially in children, given the
palatability and rarity of side effects. This study aims to compare usual care vs. usual care
plus Arnica 1M* (oral) or the placebo for management of pain in acute musculoskeletal
extremity injuries without fracture by utilizing a double-blind clinical trial design. The
primary outcome is to determine if subjects use less ibuprofen when given Arnica 1M.